These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25130613)

  • 21. Collagen-binding microbial surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-positive bacteria inhibit complement activation via the classical pathway.
    Kang M; Ko YP; Liang X; Ross CL; Liu Q; Murray BE; Höök M
    J Biol Chem; 2013 Jul; 288(28):20520-31. PubMed ID: 23720782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
    Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
    J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis.
    Ospelt C; Bang H; Feist E; Camici G; Keller S; Detert J; Krämer A; Gay S; Ghannam K; Burmester GR
    Ann Rheum Dis; 2017 Jul; 76(7):1176-1183. PubMed ID: 28183721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement activation by IgG containing immune complexes regulates the interaction of C1q with its ligands.
    Hester CG; Frank MM
    Mol Immunol; 2019 Dec; 116():117-130. PubMed ID: 31634815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C1q A08 Is a Half-Cryptic Epitope of Anti-C1q A08 Antibodies in Lupus Nephritis and Important for the Activation of Complement Classical Pathway.
    Wu WJ; Tan Y; Liu XL; Yu F; Zhao MH
    Front Immunol; 2020; 11():848. PubMed ID: 32536911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
    Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
    J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.
    Hwang HY; Duvall MR; Tomlinson S; Boackle RJ
    Mol Immunol; 2008 May; 45(9):2570-80. PubMed ID: 18313756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pattern of apolipoprotein A-I lysine carbamylation reflects its lipidation state and the chemical environment within human atherosclerotic aorta.
    Battle S; Gogonea V; Willard B; Wang Z; Fu X; Huang Y; Graham LM; Cameron SJ; DiDonato JA; Crabb JW; Hazen SL
    J Biol Chem; 2022 Apr; 298(4):101832. PubMed ID: 35304099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
    Deveuve Q; Lajoie L; Barrault B; Thibault G
    Front Immunol; 2020; 11():168. PubMed ID: 32117299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.
    Tammen A; Derer S; Schwanbeck R; Rösner T; Kretschmer A; Beurskens FJ; Schuurman J; Parren PW; Valerius T
    J Immunol; 2017 Feb; 198(4):1585-1594. PubMed ID: 28062698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
    J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation.
    Kovacs H; Campbell ID; Strong P; Johnson S; Ward FJ; Reid KB; Eggleton P
    Biochemistry; 1998 Dec; 37(51):17865-74. PubMed ID: 9922153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.
    Beers SA; Chan CH; James S; French RR; Attfield KE; Brennan CM; Ahuja A; Shlomchik MJ; Cragg MS; Glennie MJ
    Blood; 2008 Nov; 112(10):4170-7. PubMed ID: 18583569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent inhibition of the classical pathway of complement by a novel C1q-binding peptide derived from the human astrovirus coat protein.
    Gronemus JQ; Hair PS; Crawford KB; Nyalwidhe JO; Cunnion KM; Krishna NK
    Mol Immunol; 2010; 48(1-3):305-13. PubMed ID: 20728940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New insights into the molecular mechanisms of classical complement activation.
    Kojouharova M; Reid K; Gadjeva M
    Mol Immunol; 2010 Aug; 47(13):2154-60. PubMed ID: 20542571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies.
    Lohse S; Peipp M; Beyer T; Valerius T; Dechant M
    Arch Immunol Ther Exp (Warsz); 2010 Aug; 58(4):303-12. PubMed ID: 20508996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IgG4 antibodies from patients with asymptomatic bancroftian filariasis inhibit the binding of IgG1 and IgG2 to C1q in a Fc-Fc-dependent mechanism.
    Prodjinotho UF; Hoerauf A; Adjobimey T
    Parasitol Res; 2019 Oct; 118(10):2957-2968. PubMed ID: 31485865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein carbamylation links inflammation, smoking, uremia and atherogenesis.
    Wang Z; Nicholls SJ; Rodriguez ER; Kummu O; Hörkkö S; Barnard J; Reynolds WF; Topol EJ; DiDonato JA; Hazen SL
    Nat Med; 2007 Oct; 13(10):1176-84. PubMed ID: 17828273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding of the human complement subcomponent C1q to hybrid mouse monoclonal antibodies.
    Koolwijk P; Boot JH; Griep R; Bast BJ
    Mol Immunol; 1991 Jun; 28(6):567-76. PubMed ID: 1861677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System.
    Laursen NS; Pedersen DV; Gytz H; Zarantonello A; Bernth Jensen JM; Hansen AG; Thiel S; Andersen GR
    Front Immunol; 2020; 11():1504. PubMed ID: 32849513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.